Gabriela Hobbs: Emerging Myelofibrosis Therapies at EHA 2026
Gabriela Hobbs, Leukemia Clinical Director at Massachusetts General Hospital, Associate Professor at Harvard Medical School, shared Priya Sriskandarajah’s post on LinkedIn:
“Thankful for the opportunity to discuss emerging therapies in Myelofibrosis at this year’s EHA in lovely Sweden with Stefan Schleding, Gonzalo Carreño and Steffen Koschmieder.”
Priya Sriskandarajah, Consultant Haematologist at Guy’s and St Thomas’ NHS Foundation Trust, shared a post on LinkedIn:
“Next session covering management of cytopenic myelofibrosis – a very challenging cohort but some exciting new therapies coming especially combination options.
Excellent presentations by Stefan Scheding, Gonzalo Carreno and Gabriela Hobbs with chair Steffen Koschmieder.”
Stay updated with Hemostasis Today.
-
Jun 17, 2026, 09:54Shadi Tabibian: Improving Outcomes Through Accurate VWD Subclassification
-
Jun 17, 2026, 09:47Nihal Mesmoudi: Inspired by Scientific Excellence at ICMES 2026
-
Jun 17, 2026, 09:26Nicolas Gendron: Join the Conversation on Antithrombotic Stewardship at ISTH 2026
-
Jun 17, 2026, 09:19Natalia Schütz: Translating Scientific Advances into Better Patient Outcomes
-
Jun 17, 2026, 05:21Finn Guo: Exploring Payment Mechanisms for Innovative Hemophilia Therapies
-
Jun 17, 2026, 04:59Wolfgang Miesbach: One-Time CRISPR Therapy Reduces Hereditary Angioedema Attacks by 87%
-
Jun 17, 2026, 04:47Ganesh Mohan: Celebrating the Heroes of Healthcare on World Blood Donor Day 2026
-
Jun 17, 2026, 04:31Ekrem Unal: Navigating the Budget Impact of Next-Generation Hemophilia Therapies in Turkey
-
Jun 17, 2026, 04:06Simon Zhao: Patient Community Promise 2025 Takes the Golden Snail Award at 14th China Rare Disease Summit